Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -11.85% is 45% below its 1-year average of -8.19%, near the low end of its 1-year range (-11.85%–-1.64%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -11.85%.
RETURN ON EQUITY (ROE)
-11.85%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.02%
median of 703 covered companies
CURRENT VS SECTOR MEDIAN
+71.10%
vs the sector median at left
Park Dental Partners, Inc. Common Stock
Market Cap
$93.48M
Return on Equity (ROE)
-11.85%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$90.37M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$90.16M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$96.06M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$90.32M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
Market Cap
$89.78M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$90.07M
Return on Equity (ROE)
-477.87%
TTM Avg
-156.51%
3Y Avg
-83.51%
5Y Avg
-25.98%
Market Cap
$96.96M
Return on Equity (ROE)
-461.14%
TTM Avg
-233.39%
3Y Avg
-227.67%
5Y Avg
-163.94%
Market Cap
$89.60M
Return on Equity (ROE)
-105.20%
TTM Avg
-53.79%
3Y Avg
-41.98%
5Y Avg
-32.71%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Park Dental Partners, Inc. Common Stock (PARK) | $93.48M | -11.85% | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | -268.09% | -238.76% | -155.55% | -124.74% |
| electroCore, Inc. (ECOR)vs › | $90.16M | N/A | 329.82% | 69.21% | 21.28% |
| Conexeu Sciences Inc. (CNXU)vs › | $96.06M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.32M | 48.20% | -54.60% | -54.70% | -44.17% |
| Equillium, Inc. (EQ)vs › | $89.78M | -32.15% | -60.32% | -93.79% | -79.41% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $90.07M | -477.87% | -156.51% | -83.51% | -25.98% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $96.96M | -461.14% | -233.39% | -227.67% | -163.94% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.60M | -105.20% | -53.79% | -41.98% | -32.71% |
| Korro Bio, Inc. (KRRO)vs › | $97.49M | -103.31% | -140.03% | -67.31% | -49.97% |
ROE
-11.9%
ROA
-1.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -11.85% |
| 2026-03-31 | -11.07% |
| 2025-12-31 | -1.64% |
